| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advancing Rheumatology Care Through Machine Learning
|
Hügle, Thomas
|
|
|
|
2 |
p. 87-96
|
artikel
|
| 2 |
A Principles Framework for Digital Provision of Medical Information for Healthcare Professionals
|
Mohamed, Susan
|
|
|
|
2 |
p. 103-109
|
artikel
|
| 3 |
A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016
|
Ogar, Comfort Kunak
|
|
|
|
2 |
p. 145-157
|
artikel
|
| 4 |
A Transition to Targeted or ‘Smart’ Vaccines: How Understanding Commensal Colonization Can Lead to Selective Vaccination
|
Beitelshees, Marie
|
|
|
|
2 |
p. 95-102
|
artikel
|
| 5 |
Cannabidiol and Other Phytocannabinoids as Cancer Therapeutics
|
Nahler, Gerhard
|
|
|
|
2 |
p. 99-129
|
artikel
|
| 6 |
Clinical Presentations of Drug-Induced Hyperprolactinaemia: A Literature Review
|
Junqueira, Daniela R.
|
|
|
|
2 |
p. 153-166
|
artikel
|
| 7 |
Considerations for Effective Communication of Medical Information
|
Power, Eddie G. M.
|
|
|
|
2 |
p. 97-101
|
artikel
|
| 8 |
COVID-19: Reasons for Guarded Optimism
|
Snell, Noel
|
|
|
|
2 |
p. 67-69
|
artikel
|
| 9 |
Decentralisation in Clinical Trials and Patient Centricity: Benefits and Challenges
|
Sinha, Shubhadeep D.
|
|
|
|
2 |
p. 109-120
|
artikel
|
| 10 |
Digital Therapies (DTx) as New Tools within Physicians’ Therapeutic Arsenal: Key Observations to Support their Effective and Responsible Development and Use
|
Bélisle-Pipon, Jean-Christophe
|
|
|
|
2 |
p. 121-127
|
artikel
|
| 11 |
Drugs in Clinical Development for HIV: Summary and Table
|
|
|
|
|
2 |
p. 105-111
|
artikel
|
| 12 |
Drugs in Clinical Development for Renal Cancer Summary and Table
|
|
|
|
|
2 |
p. 75-84
|
artikel
|
| 13 |
Effect of Caffeine Consumption on Cardiovascular Disease: An Updated Review
|
Khiali, Sajad
|
|
|
|
2 |
p. 139-151
|
artikel
|
| 14 |
Emergency Approval Mechanisms for Human Vaccines in India
|
Mehrotra, Nidhi
|
|
|
|
2 |
p. 121-132
|
artikel
|
| 15 |
Evaluating the Effectiveness of Apixaban Additional Risk Minimisation Measures Using Surveys in Europe
|
Mayall, Steve
|
|
|
|
2 |
p. 123-135
|
artikel
|
| 16 |
Female Problems: Women’s Health Mustn’t be Ghettoized in the Uterus
|
Pitts, Peter J.
|
|
|
|
2 |
p. 75-77
|
artikel
|
| 17 |
Forum
|
|
|
|
|
2 |
p. 117-127
|
artikel
|
| 18 |
Forum
|
|
|
|
|
2 |
p. 117-128
|
artikel
|
| 19 |
Impact of Advantage in Tumor Response on the Correlation Between Progression-Free Survival and Overall Survival: Meta-Analysis of Clinical Trials in Patients with Advanced Non-Small Cell Lung Cancer
|
Yoshida, Yosuke
|
|
|
|
2 |
p. 81-92
|
artikel
|
| 20 |
Klaus Rose. Considering the Patient in Pediatric Drug Development: How Good Intentions Turned into Harm
|
Striano, Pasquale
|
|
|
|
2 |
p. 137-138
|
artikel
|
| 21 |
Major Pharmaceutical Conferences and Courses: June to July 2022
|
|
|
|
|
2 |
p. 143-145
|
artikel
|
| 22 |
Major Pharmaceutical Conferences and Courses: June to July 2021
|
|
|
|
|
2 |
p. 139-141
|
artikel
|
| 23 |
Major Pharmaceutical Conferences and Courses: June to July 2023
|
|
|
|
|
2 |
p. 167-170
|
artikel
|
| 24 |
Meaningful Within-Patient Change in Subjective Total Sleep Time in Patients with Insomnia Disorder: An Analysis of the Sleep Diary Questionnaire Using Data from Open-Label and Phase III Clinical Trials
|
Phillips-Beyer, Andrea
|
|
|
|
2 |
p. 133-144
|
artikel
|
| 25 |
Medical Affairs and Innovative Medicinal Product Strategy Development
|
Krendyukov, Andriy
|
|
|
|
2 |
p. 71-82
|
artikel
|
| 26 |
Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core
|
Fulford-Smith, Antony
|
|
|
|
2 |
p. 63-69
|
artikel
|
| 27 |
Medical Information Delivering Improved Customer Experience: A Guide
|
Guillot, Pete
|
|
|
|
2 |
p. 111-119
|
artikel
|
| 28 |
Medicines Regulatory Science Expertise in Africa: Workforce Capacity Development and Harmonisation Activities Towards the Establishment of the African Medicines Agency
|
Ncube, Bakani Mark
|
|
|
|
2 |
p. 83-97
|
artikel
|
| 29 |
Physician Awareness of the Safe Use of Cyproterone Acetate in Europe: A Survey on the Effectiveness of Additional Risk Minimization Measures
|
Sweeney, Carolyn
|
|
|
|
2 |
p. 145-156
|
artikel
|
| 30 |
Potential of Artificial Intelligence to Accelerate Drug Development for Rare Diseases
|
Napolitano, Giulio
|
|
|
|
2 |
p. 79-86
|
artikel
|
| 31 |
Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program
|
Speers, Marjorie A.
|
|
|
|
2 |
p. 89-98
|
artikel
|
| 32 |
Quantitative Methods for Safety Monitoring of Rare Serious Adverse Events
|
Duke, Susan P.
|
|
|
|
2 |
p. 113-118
|
artikel
|
| 33 |
Regulatory Approval Scenario of Biosimilars in Pediatric Patients in the United States and European Union
|
Radhakrishna, Swetha
|
|
|
|
2 |
p. 93-112
|
artikel
|
| 34 |
The Carbon Costs of In-Person Versus Virtual Medical Conferences for the Pharmaceutical Industry: Lessons from the Coronavirus Pandemic
|
Gattrell, William T.
|
|
|
|
2 |
p. 131-142
|
artikel
|
| 35 |
The conect4children (c4c) Consortium: Potential for Improving European Clinical Research into Medicines for Children
|
Turner, Mark A.
|
|
|
|
2 |
p. 71-79
|
artikel
|
| 36 |
The Qualitative Value of Facilitated Regulatory Pathways in Europe, USA, and Japan: Benefits, Barriers to Utilization, and Suggested Solutions
|
Bujar, Magdalena
|
|
|
|
2 |
p. 113-122
|
artikel
|
| 37 |
Using Patient Perspectives to Inform Better Clinical Trial Design and Conduct: Current Trends and Future Directions
|
Faulkner, Stuart D.
|
|
|
|
2 |
p. 129-138
|
artikel
|
| 38 |
Why Oncology Global Safety Teams Should Develop the Safety Section of the Study’s Target Product Profile (TPP)
|
Kieffer, Michael E.
|
|
|
|
2 |
p. 97-108
|
artikel
|
Tijdschrift beschrijving